Lonza Introduces Light Path: Streamlined Process Development and Custom Material Supply for Discovery to Early Clinical Developm

Lonza Introduces Light Path: Streamlined Process Development and Custom Material Supply for Discovery to Early Clinical Development

 

  • Simple and efficient supply of custom biological material (mg to kg)
  • Minimal scope offering tailored to meet immediate development goals

• Leverage of Lonza's optimized platforms for improved turnaround times and lower costs

 

Basel, Switzerland, 21 June 2011 - Lonza today announces the launch of Light PathTM: An efficient and focused material supply service offering for early stage development of novel biologics. The new streamlined and minimal scope development and manufacturing services are available for both mammalian and microbial applications.

"Light Path TM is a collection of basic supply services that give customers a simpler, faster, and more cost-effective way to obtain biological material," said Janet White, Head of Lonza Development Services. "We've designed Light PathTM for customers whose short-term early stage goals are of paramount importance and who still want access to Lonza's renowned experience, experts, facilities and technologies."

Lonza has worked over the past few decades to continually improve its microbial and mammalian development platforms; the robustness of these platforms has allowed for a limited and appropriate set of services focused on early development milestones. Lonza is offering Light PathTM to customers worldwide from all five of its biological development sites: Slough, UK; Cambridge, UK; Visp, Switzerland; Hopkinton, Massachusetts (USA); and Tuas, Singapore.

About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at http://www.lonza.com.


For further Information

Customer Inquiries, please contact:

Ryan Scanlon
Lonza Development Services, North America
Tel +1 201 316 9383
[email protected]

Shiva Khalafpour
Lonza Development Services, Europe & Asia
Tel +44 1753 504383
[email protected]


For further Information

Lonza Group Ltd
Head of Corporate Communications
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
[email protected]

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
[email protected]

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
[email protected]
 

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.